MRK240628C95000
- 0.00
- 0.000.00%
Merck & Co Newsroom
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Deutsche Numis Downgrades Merck & Co(MRK.US) to Hold Rating, Raises Target Price to $140
Express News | Merck Shares Are Trading Higher After the Company and Orion Announced the Mutual Exercise of an Option to Convert the Companies' Ongoing Co-development and Co-commercialization Agreement for Opevesostat Into an Exclusive Global License for Merck
Market Whales and Their Recent Bets on MRK Options
Express News | Merck Shares up 3.8%
Orion Upgrades FY24 Outlook After Modifying Agreement With Merck & Co
Merck, Orion Convert Collaboration Into Exclusive License
Express News | N-Power Medicine: Collaborates With Merck to Expand Oncologist and Patient Access to Clinical Trials
Express News | Merck And Orion Announce Mutual Exercise Of Option To Convert Opevesostat Co-Commercialization Agreement Into An Exclusive Global License For Merck; Orion Now Eligible For Development Milestones Up To $30M, Regulatory Milestones Up To $625M, And Sales...
Express News | Merck & Co Inc - Orion Eligible for up to $1.63 Billion in Milestone Payments
Express News | Merck & Co Inc: Orion Is Now Eligible to Receive Development Milestone Payments up to $30 Mln, Regulatory Milestone Payments up to $625 Mln
Express News | Merck & Co Inc - Gains Global Exclusive Rights to Opevesostat
Express News | Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational Cyp11a1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Express News | Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
Dawn Health Et Merck Collaborent Pour Soutenir La Prise En Charge Des Troubles De La Croissance
Dawn Health and Merck Are Collaborating to Support Growth Disorders Care
Questor: This 'wonder Drug' Firm Is Being Backed by Top Fund Managers
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
June 28, the top 20 turnover of US stocks: poor performance expectations, Nike plunges 20%.
Nvidia, the top trading volume stock in the US on Friday, fell by 0.36%, with a turnover of 38.914 billion US dollars, and its market cap remained above 3 trillion US dollars. The stock fell 2.4% this week, and rose 12.7% in June, nearly 150% in the first half of the year. Nvidia stock price is currently entering a high-end shock, but according to Jackson, a hedge fund manager at EMJ Capital, the stock price of Nvidia is still relatively cheap based on expected P/E ratio. He expects that Nvidia's stock price will continue to rise and may reach $250 at the end of the year - doubling on the basis of the current stock price. If this prediction comes true, the market cap of Nvidia will
What's Going On With Merck Stock On Friday?